Sanofi, Joslin Diabetes Center enter collaboration

PARIS — A drug maker and a teaching and research affiliate of Harvard Medical School announced a new collaboration to promote the development of new medicines for the treatment of diabetes and related disorders.

Sanofi and Joslin Diabetes Center said their collaboration will "focus on four key areas within diabetes and related metabolic disorders to identify potential new biologics or small drug candidates for the treatment of late complications of diabetes and new insulin analogs with more targeted efficacy, [while] research will address the challenges of insulin resistance and personalized medicine, with the overall aim of improving the lives of people living with diabetes."

Under the terms of the agreement, Sanofi has options to commercialize the results of the research, while both parties will have access to intellectual property for internal research use. Financial details of the collaboration were not disclosed.

Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.

Login or Register to post a comment.